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In Brief
The DNA methylcytosine dioxygenase Tet2 functions as a tumor suppressor in multiple contexts, including hematopoietic malignancies. Pan et al. now reveal a tumor-promoting role for Tet2, whereby Tet2 functions to sustain an immunosuppressive program in myeloid cells that in turn dampens the anti-tumor T cell response.
SUMMARY
Ten-Eleven-Translocation-2 (Tet2) is a DNA methylcytosine dioxygenase that functions as a tumor suppressor in hematopoietic malignancies. We examined the role of Tet2 in tumor-tissue myeloid cells and found that Tet2 sustains the immunosuppressive function of these cells. We found that Tet2 expression is increased in intratumoral myeloid cells both in mouse models of melanoma and in melanoma patients and that this increased expression is dependent on an IL-1R-MyD88 pathway. Ablation of Tet2 in myeloid cells suppressed melanoma growth in vivo and shifted the immunosuppressive gene expression program in tumor-associated macrophages to a proinflammatory one, with a concomitant reduction of the immunosuppressive function. This resulted in increased numbers of effector T cells in the tumor, and T cell depletion abolished the reduced tumor growth observed upon myeloid-specific deletion of Tet2. Our findings reveal a non-cellintrinsic, tumor-promoting function for Tet2 and suggest that Tet2 may present a therapeutic target for the treatment of non-hematologic malignancies.
INTRODUCTION
Tumor-tissue myeloid cells have important roles in anti-tumor immunity and tumor progression. Monocytes, macrophages, and granulocytes are actively recruited to tumors where they interact with the tumor microenvironment, often to accelerate tumor progression. Tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) are often regarded as having immunosuppressive functions that promote tumor growth, in part by suppressing adaptive immune responses to tumor cells (Marvel and Gabrilovich, 2015; Ostuni et al., 2015; Qian and Pollard, 2010; Yadav and Delamarre, 2016) . TAMs are phenotypically and functionally distinct from tissue-resident macrophages (Franklin et al., 2014) . The tumor microenvironment acts on the gene expression program of TAMs to establish and maintain immunosuppressive functions (Amit et al., 2016; Church and Galon, 2015; Colegio et al., 2014; Noy and Pollard, 2014) . Factors responsible for the establishment and maintenance of TAM functions are beginning to emerge (Colegio et al., 2014) . In particular, proteins associated with the regulation of DNA methylation, and thereby gene expression, present interesting candidates.
Ten-Eleven-Translocation-2 (Tet2) is an important tumor suppressor within the hematopoietic system. Loss-of-function mutations in TET2, such as mutations resulting in readingframeshifts and early stop codons, are frequently found in myeloid malignancies (Delhommeau et al., 2009; Figueroa et al., 2010; Ko et al., 2010; Langemeijer et al., 2009 ). Deletion of Tet2 in hematopoietic stem cells (HSCs) leads to increased self-renewal of HSCs and the expansion of the myeloid compartment, particularly the myelomonocytic lineage (Ko et al., 2011; Li et al., 2011; Moran-Crusio et al., 2011; Quivoron et al., 2011) , further supporting a tumor-suppressive role for Tet2. Tet2, together with Tet1 and Tet3, form the Tet family, which biochemically catalyzes 5-methylcytosine (5mC) conversion to 5-hydroxymethylcytosine (5hmC) and its derivatives to mediate DNA demethylation Huang and Rao, 2014; Ito et al., 2011; Tahiliani et al., 2009; Wu and Zhang, 2011) . Recent studies have also revealed non-catalytic functions of Tet2 (Chen et al., 2013; Zhang et al., 2015) , underscoring diverse mechanisms by which Tet2 regulates gene expression.
Although the function of Tet2 as a hematopoietic tumor suppressor is well established, it is unclear whether Tet2 activity within hematopoietic cells could impact solid tumors. In particular, the expansion of myelomonocytic lineages upon Tet2 deletion in HSCs raises the question of whether distinct functions of Tet2 may exist in these cells. Furthermore, recent findings of somatic TET2 mutations in peripheral blood cells, present in both healthy human individuals and solid cancer patients (Busque et al., 2012; Genovese et al., 2014; Jaiswal et al., 2014; Xie et al., 2014) , raise the possibility that TET2 mutant myeloid cells may be ''genetically reprogrammed'' to elicit altered functions in solid cancer. Roles for Tet2 in T cells (Ichiyama et al., 2015; Tsagaratou et al., 2014; Yang et al., 2015) and dendritic cells in response to pathogens (Zhang et al., 2015) have been recently described. Whether Tet2 could impact gene expression and thereby function of TAMs and how Tet2 might be regulated by the tumor environment remains to be investigated.
Successes of immune-checkpoint inhibitors in melanoma patients highlight the potential of immune cells in regulating melanoma biology (Bhatia and Thompson, 2014; Callahan, 2016) . Human melanomas harbor activation mutations in BRAF V600E in $65% of cases (Chin, 2003; Davies et al., 2002) , which often co-occur with loss-of-function mutations in tumor suppressors such as PTEN and CDKN2A. A mouse model of melanoma bearing the Braf V600E and Pten null mutations recapitulates key features of human melanoma (Dankort et al., 2009) . Treatment of these mice with an inhibitor of the macrophage colony-stimulating factor receptor (Csf1r, important for macrophage differentiation, proliferation, and survival) delayed tumorigenesis, suggesting the importance of TAMs in promoting tumor development in this model (Ngiow et al., 2015) .
Here we explored the impact of myeloid-specific deletion of Tet2 on tumor growth using two murine melanoma models. Contrary to the recognized role of Tet2 as a tumor suppressor, we found that Tet2 maintains the immunosuppressive functions of tumor-tissue macrophages to promote tumor growth. Tet2 expression in TAMs was regulated via an interleukin-1 receptor (IL-1R)-Myd88 pathway, and deletion of Tet2 resulted in changes in gene expression and associated functional polarization of TAMs. Thus, Tet2, a protein regulating the DNA methylation landscape, mediates myeloid immunosuppression and melanoma tumor progression.
RESULTS

Increased Expression of Tet2 in TAMs and MDSCs during Melanoma Progression
As a main model in our study, we used the YUMM1.7 murine melanoma cell line, which was derived from the Braf V600E Pten
Cdkn2a
À/À mouse model (Dankort et al., 2009 ). YUMM1.7
robustly gives rise to melanoma in syngeneic wild-type host mice with a substantial contribution of TAMs to tumor mass (Ho et al., 2015; Meeth et al., 2016) , similar to what is often observed in human melanoma. We first evaluated the RNA expression levels of Tet family members in myeloid cells after injecting YUMM1.7 cells subcutaneously into wild-type mice ( Figure 1A ). We found that TAMs isolated from tumor tissue had significantly higher Tet2 mRNA expression than macrophages isolated from peritoneum or bone marrow of control tumor-free mice ( Figure 1B ). In contrast, Tet3 mRNA expression levels were similar between these macrophage populations ( Figure 1B ), whereas Tet1 transcripts were barely detectable. We next harvested TAMs at two different time points during tumor progression (early and late stages) and determined that the amounts of Tet2 transcripts in TAMs increased during melanoma progression, whereas no change in Tet3 expression was observed ( Figure 1C) . Consistent with the increase of Tet2 mRNA expression, global 5hmC levels in TAM genomic DNA were increased by $2-fold during melanoma progression ( Figure 1D Figure S1A for sorting scheme). Overall, intratumoral myeloid cells had $2-fold higher Tet2 mRNA levels than the corresponding splenic populations from tumor-bearing mice, which in turn were $2-fold higher than corresponding splenic populations from non-tumor-bearing mice ( Figure 1E ). We also observed that granulocytic populations had 2-to 3-fold lower Tet2 mRNA amounts than macrophage and monocytic populations from the same tissue, while Tet3 RNA levels were similar across all these subsets ( Figure 1E ). Similar results were observed when another melanoma model was used, induced by injecting B16-OVA cells (Figures S1B and S1C 
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Pten À/À Cdkn2a À/À (YUMM1.7) melanoma cells were injected subcutaneously. Tumorassociated macrophages (TAMs) were harvested at 1 and 4 weeks. (B) Tet2 and Tet3 transcript amounts were determined in peritoneal macrophages (PM) and bone marrow-resident macrophages (BMRMs) from tumor-free mice and TAMs (4 weeks after tumor cell injection) from tumor-bearing wild-type (WT) mice, using qRT-PCR. n = 7. Normalized RNA expression is shown with each dot reflecting one mouse. (C) TAMs were harvested from WT mice at 1 week (n = 6) and 4 weeks (n = 7) after tumor cell injection. (Carmi et al., 2009; Cataisson et al., 2012; Lewis et al., 2006; Voronov et al., 2014) and that IL-1 cytokines are elevated in primary melanoma tissues (Voronov et al., 2003 Figure 3D ). As negative controls, the mRNA levels of Ifnb were unchanged ( Figure 3D ). We also observed that tumor burden was largely reduced in Il1r1 À/À mice compared to WT mice (Figure S2A) . To determine the effect of acute loss of IL-1R signaling on Tet2 expression in TAMs and on tumor progression, we established tumor development in WT mice and acutely blocked IL-1R signaling afterward (from day 9 after tumor cell injection) by administrating an IL-1R antagonist, IL-1Ra, in vivo ( Figure 3E ). IL-1Ra treatment led to a gradual reduction in tumor size (Figure 3F) and reduced Vegfa and Mmp9 expression in TAMs, both at an early time point before significant tumor size reduction was observed (day 12) and at a later time point when tumor size reduction became obvious (day 18) ( Figure 3G ). At both time points, we observed significant reductions in Tet2 RNA amounts in TAMs ( Figure 3G ). These data support that Tet2 expression in TAMs is positively regulated by IL-1R signaling within the tumor microenvironment.
MyD88 is an important adaptor protein in the IL-1R-signaling pathway (Muzio et al., 1997; Wesche et al., 1997 Figure 3I ), while the levels of Ifnb were unchanged (Figure 3I) . These results support a role for MyD88 in controlling Tet2 expression in TAMs. IL-1R signaling has been shown to increase Il1b gene expression (Cataisson et al., 2012) . Consistent with an IL-1R-MyD88 pathway regulating Tet2 expression, we observed a significant correlation between Tet2 and Il1b mRNA amounts when examining TAMs harvested from murine melanomas, but not between Tet3 and Il1b RNA levels ( Figure 3J ). Interestingly, when examining peripheral and intratumoral myeloid cells from human melanoma patients, we also observed a significant correlation between TET2 and IL1B transcripts, as well as between those of TET2 and IL1A ( Figures S2B and S2C ), suggesting that this regulatory pathway operates similarly in human cells. Taken together, the data above support an IL-1R-MyD88-Tet2 pathway in the tumor microenvironment regulating melanoma progression in vivo.
Tet2 Sustains the Expression of Immunosuppressive Genes in TAMs
To understand how Tet2 in myeloid cells regulates melanoma progression, we performed RNA-seq analysis on TAMs isolated from tumor-bearing mice of WT and Mye-Tet2-null genotypes. We observed that genes with reduced mRNA expression in Mye-Tet2-null TAMs were enriched for signatures of M2 immunosuppressive macrophages, whereas genes with increased expression in Mye-Tet2-null TAMs were enriched for signatures of M1 proinflammatory macrophages ( Figure 4A ). We further validated the reduced mRNA expression of a number of genes with immunosuppressive functions, including Arg1, Mgl2, and Il4 ( Figure 4B ; Biswas et al., 2008; Rawal et al., 2011; Sharda et al., 2011) . At the same time, the mRNA amounts of a number of pro-inflammatory cytokines were increased, including Il6, Il12b, and Tnfa ( Figure 4B ). These data indicate that deletion of Tet2 shifted the balance between immunosuppressive and proinflammatory polarization of TAMs. The effect of Tet2 deletion on immunosuppressive gene expression was similarly observed when WT or Tet2-null BMDMs were polarized in vitro with IL-4 ( Figure S3A ). The mRNA expression levels of several immunosuppressive genes such as Arg1 and Mgl2 were reduced in both Mye-Tet2-null TAMs and IL-4 polarized Tet2-null BMDMs (Figures 4B and S3B) . We further evaluated the protein activity of Arg1 and confirmed decreased Arg1 activity in Tet2-null TAMs ( Figure 4C ) and BMDMs ( Figure S3C ). These data establish that Tet2 is required to maintain the expression of multiple immunosuppressive genes in TAMs.
We next asked whether the reduced expression of immunosuppressive genes can be explained by changes in local 5hmC alterations. Due to the difficulty of obtaining large numbers of TAMs, we performed genome-wide 5hmC DNA immunoprecipitation (5hmC-DIP) mapping in naive (M0) and polarized (M2) BMDM cells from WT and Tet2-null mice. Overall, 5hmC levels around protein-coding genes were mildly decreased in Tet2-null cells ( Figure S3D ). Among the genes regulated by Tet2, Arg1 showed putative differential 5hmc peaks in gene-proximal regions ( Figure S3E ). We observed that the upstream region of Arg1 contained a consistently reduced 5hmC peak in Tet2-null cells. The peak region was located close to a known enhancer region of Arg1 ( Figure S3F ; Sharda et al., 2011) . Using DNA immunoprecipitation (DIP)-qPCR, we confirmed the decreased 5hmC levels at this region in Tet2-null BMDM cells and observed a concomitant increase in 5mC levels ( Figure S3G ). Similar results were also observed in Mye-Tet2-null TAMs ( Figure S3H ). These data suggest that Tet2 is required to maintain a low 5mC level at the Arg1 gene locus by increasing 5hmC levels, implying regulation of the gene by DNA demethylation. However, other immunosuppression-related genes, such as Mgl2, Klf4, and Irf4, did not show major changes in 5hmC levels in geneproximal regions. Whether these genes could be regulated through a 5hmC-independent mechanism or through 5hmC-dependent distal enhancers requires future analysis. Collectively, our data support that Tet2 maintains the expression of immunosuppressive genes in TAMs, likely through multiple mechanisms.
Reduced Immunosuppressive Functions of Tet2-Null Myeloid Cells In Vitro
Guided by the gene expression analysis, we tested whether Tet2-null TAMs and MDSCs have reduced immunosuppressive function, by an in vitro T cell activation assay. Specially, splenic CD4 + T cells were stimulated with anti-CD3 and anti-CD28 and T cell activation was determined by CFSE-based dye dilution (Doedens et al., 2010) . When co-culturing CD4 + T cells with WT TAMs, strong suppression of T cell proliferation was observed ( Figures 4D and 4E ). In contrast, the suppressive capacity was significantly reduced when Mye-Tet2-null TAMs were used, under two different T cell to TAM ratios (Figures 4D and 4E reduced in Tet2-null MDSCs, while reactive oxygen species (ROS) and iNos, Nox2, Ncf1, and Tgfb mRNA expression did not show significant changes ( Figures S4A-S4C ). We next measured the ability of intratumoral MDSCs to suppress T cells. While a decreased immunosuppressive function was observed for Tet2-null MDSCs at a T cell to MDSC ratio of 3:1 ( Figures S4D and S4E ), significant changes could not be detected when a different ratio was used ( Figure S4E ), unlike what we observed with TAMs ( Figure 4E ). These data support a reduction of immunosuppressive functions of Tet2-null TAMs and Tet2-null intratumoral MDSCs, with a stronger alteration in TAMs. Since Arg1 gene expression was significantly reduced in Tet2-null TAMs, we asked whether Arg1 is an important mediator of Tet2 function in TAMs. In the TAM and CD4 + T cell coculture, the addition of arginase inhibitor significantly reduced the immunosuppressive activity of WT TAMs, but not that of Mye-Tet2-null TAMs, leading to the abolishment of the difference on T cell suppression by these two groups of cells (Figure 4F) . On the other hand, addition of recombinant Arg1 led to an almost complete blockage of T cell proliferation for both WT and Mye-Tet2-null TAMs, again abolishing the difference between these two TAM populations ( Figure 4F ). These data support that Arg1 expression plays an important role in mediating the immunosuppressive function of Tet2 in TAMs.
Increased Tumor-Infiltrating T Cells in Mice with Myeloid-Specific Deletion of Tet2
The reduction of the expression of immunosuppressive genes and the reduction of in vitro immunosuppressive functions of Mye-Tet2-null TAMs raised the possibility that the intratumoral immune cell repertoire was shifted to favor anti-tumor functions. We thus examined multiple immune subsets ( Figure S5A ) within the YUMM1.7-initiated tumors developed in WT or Mye-Tet2-null mice. We observed that the percentages of CD45 + cells were increased in tumors from Mye-Tet2-null mice ( Figure 5A ). Within CD45 + cells, the percentages of CD3 + T cells were significantly increased, whereas those of natural killer (NK) cells, natural killer T (NKT) cells, and macrophages were unchanged, and the percentages of granulocytes were mildly decreased in tumors ( Figure 5B ). When quantifying by cell numbers per tumor volume, the differences in granulocytes were no longer observed, with a substantial increase of CD3 + T cells and mild increases of TAMs, NK cells, and NKT cells in Mye-Tet2-null tumors ( Figure 5B ). We further assessed the CD4 + and CD8 + T cell populations in tumor.
Within the T cell compartment, the levels (both percentages within CD45 + cells and cell numbers per tumor volume) of both CD4 + and CD8 + T cells were increased in Mye-Tet2-null tumors, with a stronger elevation observed for CD8 + T cells ( Figures 5C and 5D ). In contrast, the percentages of CD4 + or CD8 + cells in the spleens of the tumor-bearing mice were not significantly altered in Mye-Tet2-null mice ( Figure 5E ). Among intratumoral CD4 + T cells, the percentages of T helper 1 (Th1) effector T cells were mildly increased whereas those of the immunosuppressive regulatory T (Treg) cells were mildly decreased ( Figures 5F and 5J ). In contrast, the corresponding populations in spleens were not changed ( Figures 5G and 5K) . Similar results were observed for CD8 + T cells ( Figures 5H, 5I , 5L, and 5M). This led to an overall significant elevation of the ratio of CD8 + T cells over Treg cells, and a milder increase of the ratio of CD4 + T cells over Treg cells ( Figure 5N ). The increase in the intratumoral T cell populations in Mye-Tet2-null mice, particularly CD8 + T cells, could also be observed in the B16-OVA-initiated melanoma, indicating that this effect was not dependent on a specific tumor model ( Figures S5B-S5H) . Overall, the data here suggest a shift of the intratumoral immune environment to favor anti-tumor activity in Mye-Tet2-null mice.
T Cell Depletion Abolished the Reduced Tumor Growth Observed upon Myeloid-Specific Deletion of Tet2
We reasoned that if increased intratumoral T cells were functionally important for the reduced melanoma growth in MyeTet2-null mice, we would expect that depleting T cells could lead to a rescue of tumor size. We tested this possibility by antibody-based depletion of both CD8 + and CD4 + T cells, given the increase of both cell types observed in YUMM1.7-intiated tumors. After melanoma growth was initiated by injecting WT and Mye-Tet2-null mice with tumor cells, we treated mice with both anti-CD4 and anti-CD8 antibodies from day 7, with one dose per 7 days ( Figure 6A ). The antibody treatments effectively depleted T cells, as evidenced by the loss of CD4 + and CD8 + T cell populations in spleen, lymph node, and tumor (Figures 6B ). This treatment did not lead to any major noticeable changes in TAMs with regard to both immunostaining and gene expression (Figures S6A and S6B) . Similar to the aforementioned phenotypes, mock-treated mice bore tumors with reduce size in Mye-Tet2-null mice compared to WT controls ( Figure 6C ). T cell depletion resulted in a mild increase (1.4-fold) in tumor size in WT mice ( Figures 6C and 6E ). In contrast, T cell depletion in Mye-Tet2-null mice led to a stronger (>2.2-fold) increase in tumor size. No significant changes were observed when comparing tumor sizes in Mye-Tet2-null mice to those from WT mice upon T cell depletion ( Figure 6C ). Indeed, statistical analyses confirmed that the reduction of tumor size in Mye-Tet2-null mice were largely abolished upon T cell depletion ( Figure 6D ) and that T cell depletion had a significantly stronger effect on tumor size in Mye-Tet2-null mice than in WT control mice ( Figure 6E ). When depleting CD8 + and CD4 + T cells separately, we observed a stronger effect by CD8 + T cell depletion ( Figure S6C ), consistent with a stronger increase in intratumoral CD8 + T cells in the Mye-Tet2-null tumors. Similar effects of CD8 + and CD4 + T cell depletion were also observed in the B16-OVA-initiated tumor model ( Figures S6D  and S6E ). Taken together, these data indicate that T cell depletion rescued the reduced tumor growth phenotype in MyeTet2-null mice.
DISCUSSION
Tet2 is recognized as one of the major tumor suppressors within the hematopoietic system. It is often mutated somatically in hematopoietic cells in healthy individuals, as well as in patients with myeloid malignancies or solid tumors (Busque et al., 2012; Genovese et al., 2014; Jaiswal et al., 2014; Xie et al., 2014) . This tumor-suppressive function has been attributed to increased hematopoietic stem and progenitor cells in mice with Tet2 deletion (Ko et al., 2011; Li et al., 2011; Moran-Crusio et al., 2011; Quivoron et al., 2011) . While the expansion of myelomonocytic lineages have been observed when Tet2 is deleted in murine HSCs, it is unclear whether ablation of Tet2 in downstream myeloid cells may impact malignant processes. Here, we focus on the myeloid compartment and demonstrate that Tet2 plays a surprising tumor-promoting role in melanoma models by sustaining immunosuppressive functions of intratumoral myeloid cells. Whether this role also applies to other solid cancers awaits future exploration.
Since the cre stain we used cannot genetically distinguish the different myeloid subpopulations, it is likely that both TAMs and MDSCs contribute to the phenotype of reduced tumor growth in mice with myeloid-specific deletion of Tet2. Both TAMs and intratumoral MDSCs had higher levels of Tet2 mRNA amounts than similar splenic populations of tumor-bearing mice or tumor-free mice. The expression of Arg1, the signature gene for TAMs, M2 macrophages, and M-MDSCs, was reduced in TAMs and intratumoral MDSCs. We did not detect a change in ROS level in the intratumoral MDSC population, suggesting that G-MDSCs may be less impacted. On the gene expression level, Mye-Tet2-null TAMs showed a significant increase in the M1 macrophage signature and a concurrent decrease in the M2 macrophage signature. Which of the differentially expressed gene(s) mediates the function of Tet2 on immunosuppression? Our data support that the reduction of Arg1 is an important event downstream of Tet2 ablation. These results are consistent with myeloid Arg1 promoting tumor growth in a lung tumor model in vivo (Colegio et al., 2014; Rodriguez et al., 2005) and that Arg1 catalyzes the degradation of L-arginine from the extracellular environment to decrease antigen-specific T cell proliferation (Pauleau et al., 2004) . Our findings on Arg1, however, do not exclude the possibility that other Tet2-regulated genes, such as Mgl2, also contribute to the phenotype. Similarly, it is also possible that the increase of the M1 macrophage gene expression program in Tet2-null TAMs plays important functional roles.
TAMs are heterogeneous in terms of function and phenotype (Okabe and Medzhitov, 2014) . It is highly likely that the different activation states of TAMs reflect responses to dynamic local microenvironmental cues within the tumor (Amit et al., 2016) . We examined this topic in our murine tumor models and found an IL-1R-MyD88 pathway enhancing Tet2 expression both in vitro and in vivo. Our data on MDSCs and human melanoma specimens suggest that the regulation of Tet2 gene expression by tumor microenvironment could be extended to other myeloid populations and is conserved from mouse to human. IL-1R can be regulated by multiple ligands, including IL-1b, IL-1a, and IL-1Ra (Voronov et al., 2014) . Our work suggests that cytokines derived from tissue microenvironment can affect the DNA-methylation-related pathway in TAMs and control macrophage function. It is also interesting to note that chronic IL-1 exposure drives HSCs to precociously differentiate toward the myeloid lineage (Pietras et al., 2016) . Whether a similar pathway regulates Tet2 during HSC differentiation could be examined in the future.
Our work suggests that the DNA-methylation regulatory pathway in myeloid cells could be further explored to elucidate immune regulation of solid tumors. Other than Tet2, Tet3 and Dnmt3a have been recently reported to modulate gene For all panels, *p < 0.05; **p < 0.01; ns: not significant. Data are representative of three independent experiments. Please also see Figure S5 . expression in macrophages and control antiviral responses Xue et al., 2016) . DNMT3A is also frequently mutated in HSCs, whose ablation leads to HSC expansion and inhibition of differentiation (Cullen and Goodell, 2015) . Although TET3 is not a major target of genetic mutations in human, murine studies have revealed that combined Tet2 and Tet3 ablation leads to accelerated development of a myeloid malignancy , suggesting functional cooperation between Tet2 and Tet3. Further mechanistic studies in this area may lead to new avenues of clinical intervention.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
AUTHOR CONTRIBUTIONS
W.P. designed and conducted most of the experiments. S.Z., K.M., J.C., K.H., H.M., Z.W., C.R., J. Liu, Z.T., J.Z., and B.G. participated in the experiments. K.Q., J.Z., W.P., and J. Lu performed bioinformatics analysis. Y.L. and X.W. collected and analyzed human samples. M.B., R.A.F., and S.A.K. assisted with reagents, experimental design, and data interpretation. J. Lu supervised the study. J. Lu and W.P. wrote the manuscript.
ACKNOWLEDGMENTS
We thank Susan Kaech, Carla Rothlin, Shangqin Guo, Tae Kon Kim, Yi Yang, and Anna Baccei for helpful discussions, technical expertise, or critical review of this manuscript. We thank Mei Zhong from Yale Stem Cell Center Genomics Core for assistance with deep sequencing, which was supported by the Connecticut Regenerative Medicine Research Fund (RMRF) and the Li Ka Shing Foundation. We thank the assistance from the cores of Yale Cooperative Center of Excellence in Hematology. This work is supported in part by NIH grant R01CA149109 (to J. Lu), Connecticut RMRF grant 
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Jun Lu (jun.lu@ yale.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice
All animal experiments were performed in accordance with the guidelines of Yale University's Institutional Animal Care and Use Committee and the guidelines of NIH. All mice were housed in facilities of the Yale Animal Resources Center (YARC) with husbandry MicroBeads (Miltenyi Biotec).
Cell lines YUMM1.7 melanoma cells (Braf
V600E
Pten
) and B16-OVA cells were maintained in complete RPMI medium 1640 (Thermo Fisher), with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin/glutamine (PSG) at 37 C and 5% CO 2 . Raw264.7 cells were kept in complete Dulbecco's Modified Eagle Medium (DMEM) with 10% FBS and 1% PSG at 37 C and 5% CO 2. Raw264.7 cells were gently scraped off from culture dish using a sterile scraper when passage was needed.
METHOD DETAILS
Murine tumor models and tumor harvest YUMM1.7 melanoma cells and B16-OVA cells were injected subcutaneously into the flanks of mice (2 3 10 5 cells per injection in 100 mL PBS). Male C57BL/6J mice of 6 to 8 weeks of age were used. Tumor volume was determined by measuring the length, width and height of the tumor with a caliper, and calculated by (1/6) x p x (Length x Width x Height). The mice were euthanized on indicated days in the figures. Tumors were resected and transferred to 5 mL PBS on ice. Tumor weight was measured on a scale by transferring the specimen to a sterile Petri dish after removal of surface moisture with Kimwipes. The tumors from all experiments were then processed for flow cytometry analysis or FACS-sorting on the same day. The resected mouse tumors were mechanically dissociated with surgical scissors and digested with Collagenase IV (Worthington) and DNase I (Roche) in PBS for 30min in a 37 C shaking incubator (150 rpm). After enzymatic dissociation, the samples were transferred to ice to stop the reaction. The tumor suspension was then filtered using a 70 mm cell strainer (Becton Dickinson) and washed with the FACS buffer (0.5% FBS in PBS) and centrifuged at 1,300 rpm. at 4 C in an Eppendorf 5810R centrifuge (similar centrifugation parameters were used throughout). Red blood cells were lysed with ACK lysis buffer (Thermo Fisher) followed by washing with the FACS buffer. The samples were then resuspended in the FACS buffer. The samples were kept on ice throughout the rest of the staining procedure.
Isolation of human melanoma CD11b
+ cells from surgical tissues
The tumor tissue was placed on ice and a scalpel was used to trim off any evident stromal, fat, and necrotic portions of the tumor. The remaining tumor tissue was then finely minced with a razor blade on a Petri dish to break up large pieces > 1-2 mm in diameter. The melanoma tissue was then dissociated in a tube containing $10-30 mL of RPMI 1640 medium with Liberase Blendzyme (Roche) added at a final concentration of 60 mg/ml. Dissociation was performed in a 37 C incubator on a rocking platform with constant mixing for 45-60 min. The dissociated tissue was then filtered through a 70 mm nylon filter into a 50 mL conical tube. A 30 mL solution of PBS and 2% heat inactivated FBS was added to neutralize the dissociation enzyme. The cell suspension was centrifuged at 1500 rpm for 5 min at 4 C. The pellet was washed twice with 30 mL of PBS with 2% FBS If the initial surgical sample contained a significant amount of red blood cells, the cells pellet was resuspended in 2 mL of ACK lysis buffer (Thermo Fisher) and incubated for 1 min on ice, followed by the addition of 30 mL of PBS with 2% FBS, and centrifuged. The cells were subjected to the isolation of CD11b + cells by using CD11b MicroBeads (Miltenyi Biotec). Peripheral blood samples were similarly enriched for CD11b + cells after red cell lysis.
Overall, paired peripheral blood samples and tumor tissues were obtained from six melanoma patients. Examination of mRNA expression by qRT-PCR was performed in triplicates for each sample.
Cell and tissue collection, and FACS analysis Peritoneal macrophages were collected from the peritoneal cavity of untreated mice by injecting 10 mL of PBS followed by gentle abdominal massaging. Macrophage enrichment was performed by plating cells in RPMI with 10% FBS and 1% penicillin/ streptomycin for 2 hours at 37 C and 5% CO2. After 2 hours, non-adherent cells were removed with three PBS washes, and cells were harvested in TRIZol for RNA extraction and qPCR analysis. Bone marrow macrophages were isolated by FACS-sorting of CD11b + F4/80 + cells. Experiments were repeated twice or more times. In each experiment, cells were collected from $7 mice for each group. qRT-PCR analysis was performed with two replicates.
For flow cytometry analysis or FACS-sorting, single cell suspension form the tumor tissue was washed with the FACS buffer and stained with the following antibodies: anti-mouse CD45.2-Pacific blue antibody (Biolegend; clone, 30-F11; used at 1:100), antimouse CD11b-PE antibody (Biolegend; clone, M1/70; used at 1:200), anti-F4/80-APC antibody (eBioscience; clone BM8; used at 1:100), anti-Gr1 (Biolegend; clone RB6-8C5; used at 1:100), anti-Ly-6G-PE/Cy7 (Biolegend; clone 1A8; used at 1:400), anti-Ly-6C-APC (Biolegend; clone HK1.4; used at 1:200), anti-CD3-PE (Biolegend; clone 145-2C11; used at 1:200), anti-CD4-APC (Biolegend; clone GK1.5; used at 1:100), anti-mouse CD8a-FITC (Biolegend; clone 53-6.7; used at 1:100), anti-NK1.1-APC (Biolegend; clone PK136; used at 1:100) and anti-Ly6g-FITC (Biolegend; clone 1A8; used at 1:200) at 4 C for 15 min in the dark. The samples were then washed twice and resuspended in FACS buffer for sorting. For FACS = -sorting, live cells were first selected on the basis of forward scatter (FSC) and side scatter (SSC), followed by excluding non-single-cell events with SSC-A, SSC-W and FSC-A and FSC-W. The indicated populations were selected and sorted. Cells from other tissues were similarly processed.
For intracellular cytokine staining, cells obtained from the digested tumor mass or other sources were incubated in a tissue culture incubator for five hours at 37 C with phorbol 12-myristate 13-acetate (PMA, 50 ng/ml; Sigma), ionomycin (750 ng/ml; Sigma) and brefeldin A (10 mg/ml; Sigma). Surface staining was performed as described above with anti-mouse CD4-APC (Biolegend; clone GK1.5; used at 1:100), or anti-mouse CD8a-FITC (Biolegend; clone 53-6.7; used at 1:100). After surface staining, the cells were resuspended in Fixation/Permeabilization solution (Cytofix/Cytoperm Kit; BD Biosciences) and intracellular cytokine staining was performed according to the manufacturer's protocol with anti-mouse IFN-g-PE (Biolegend; clone XMG1.2; used at 1:100). For Foxp3 staining, the cells were not stimulated with PMA and ionomycin; instead, they were stained according to the manufacturer's protocol (Foxp3 Staining Buffer Set, eBioscience). For all flow cytometry data, each dot represents one mouse. Experiments were repeated twice or more times. For one batch of experiments, usually more than five mice were used for each group.
Differentiation and treatment of BMDMs
Total bone marrow cells were harvested from femur bones into the FACS buffer. Cell suspension was filtered through a 70 mm nylon strainer into a 50 mL tube. ACK lysis buffer (Thermo Fisher, 5 ml) was then added to lyse the red blood cells for 2 min at room temperature. To stop the lysis reaction, 20 mL RPMI with 2% FBS was added and the tube was centrifuged at 1500 rpm for 5 min at 4 C. The cell pellet was washed and resuspended in BMDM medium (30% L929-conditioned medium, 20% FBS, 10 ng/ml recombinant murine M-CSF (Biolegend, cat#576402) in RPMI 1640 medium, with 1% penicillin/streptomycin/glutamine). The cells were then plated at 2.5 3 10 6 cells per well in a sterile six-well tissue culture plate, and cultured for 7 days. To activate BMDM cells, BMDM medium was changed into DMEM medium (DMEM, 10% FBS, 1% PSG) the night before the stimulation. For IL-1b activation, 100 ng/ml IL-1b was added; for M2 activation, 20 ng/ml IL4 was added. The cells were then harvested at the indicated time points, and used in subsequent experiments. Two to three independent experiments were performed, with each containing three biological replicates or more (except for the RNA-seq samples with two replicates). qRT-PCR analysis was performed with two replicates for each sample.
RNA-Seq and data analysis RNA-Seq library preparation and sequencing for BMDM samples were performed by Yale Center for Genomic Analysis, through ribosomal RNA depletion. Sequencing was performed on an Illumina 2500 machine. RNA-Seq library preparation and sequencing for TAM samples were conducted at Yale Stem Cell Center Genomics Core facility through poly A enrichment (Illumina TruSeq Stranded mRNA Library Prep Kit). RNA-Seq fastq files were processed in the GenePattern package, by first performing TopHat alignment to the mm9 mouse genome assembly, followed by quantification by CuffDiff. The resultant fpkm data were analyzed with custom MATLAB codes. For BMDM data, differentially expressed genes were identified by ANOVA analysis between the experimental groups and time points, and further filtered for at least 1.5 fold changes. Pathway analysis was performed using DAVID and Ingenuity Pathway Analysis. For TAM data, differentially expressed genes were identified by satisfying both Student's t test nominal p value of less than 0.05 and having mean log2 expression difference of at least 1. For analysis of M1 and M2 signatures, gene set enrichment analysis (GSEA) was performed by using the Broad Institute's GSEA program, using custom gene sets. Two independent sets of signatures were used (Table S2) . M1 Signature 1 and M2 Signature 1 were derived ourselves by comparing transcriptomic data of M1 (LPS treated) and M2 (IL4 treated) BMDMs treated for 10 hours and 24 hours versus those from M0 BMDMs (not treated). M1 Signature 2 and M2 Signature 2 were copied from M1 distinct gene set and M2 distinct gene set in Jablonski et al. (Jablonski et al., 2015) with duplicate gene symbols removed. Our own M1 and M2 signatures were derived as follows. For either M1 or M2, treatment data were compared to untreated cells (M0) at 10 hour and 24 hours. Signature genes satisfied the following criteria: mean log2 fpkm expression of treated samples is more than 2; mean log2 expression of treated samples minus the mean log2 expression of M0 samples is more than log2(5); mean log2 expression of opposite polarization at 10 hour minus mean log2 expression of M0 samples is less than 0.2; signature genes satisfying the above criteria at either 10 hours or 24 hours of treatment.
Quantitative RT-PCR Total RNA was extracted from the cells and mouse tissues with TRIzol reagent (Thermo Fisher) according to the manufacturer's protocol. cDNA was synthesized with SuperScript III reagent kit (Thermo Fisher). The expression of the genes encoding mouse Tet2, Tet3, Arg1, Mgl2, Il10, Irf4 , and Klf4 etc. were quantified by real-time PCR using the SYBR Green PCR Master Mix (Thermo Fisher). All gene expression results were normalized to the expression of the housekeeping gene Rpl13a. Amplification of cDNA was performed on an ABI Prism 7900 HT cycler (Applied Biosystems) or a Biorad CFX96 machine. Gene expression data were analyzed by calculating the threshold values (Ct) and fold changes relative to an internal control. Primers used in this study are listed in Table S1 . qRT-PCR analysis of gene expression was usually performed with more than two technical replicates.
5hmC DIP
For genome-wide analysis of 5hmC distributions, 5hmC DIP analysis was performed. Library preparation was performed according to the protocols in NEBNext DNA Library Prep Master Mix Set for Illumina (NEB, E6040). Briefly, genomic DNA was sonicated to $200bp fragments. Ten micrograms of sonicated genomic DNA were then used to ligate with the adaptor, provided in the kit, following the manufacturer's instructions. Sonicated and adaptor-ligated genomic DNA fragments were incubated with 5 mL of 5hmC antibody (Active Motif, 39791) at 4 C overnight in a final volume of 500 mL in DIP buffer (10 mM sodium phosphate, pH 7.0, 140 mM NaCl, 0.05% Triton X-100). The immunoprecipitated DNA fragments were enriched with Dynabeads Protein G (Thermo Fisher) and amplified with the primers provided in the NEBNext Multiplex Oligos for Illumina preparation kit (NEB, E7335). The prepared libraries were sequenced on an Illumina HiSeq2000 machine at Yale Stem Cell Center. One library was prepared for each condition indicated.
In vitro T cell activation assay Mouse splenic CD4 + T cells were isolated by MACS-based purification (Stem Cell Technologies). T cells were labeled with 1 mM CFSE (Invitrogen) in pre-warmed PBS for 10 min at 37 C. The CFSE-labeled CD4 + T cells were then plated in complete RPMI media (with 10% FBS, 2mM glutamine, 1% penicillin/streptomycin) supplemented with 0.05 M b-mercaptoethanol in round bottom 96-well plates (2.5 3 10 4 cells per well). The plates were pre-coated with 1 mg ml À1 anti-CD3 (eBioscience clone 145-2C11). 5 mg ml À1 anti-CD28 (eBioscience clone 37.51) antibodies were directly added into the medium. Purified myeloid cells (TAMs or MDSCs) were added in indicated ratios and plates were incubated at 37 C and in 5% CO 2 . In experiments with BMDMs, BMDM cells were cultured under M0 or M2 conditions for more than 24h, and then the culture supernatants (200 ul) were mixed with the CFSE-labeled T cells and were added into the 96-well assay plates pre-coated with 1 mg ml À1 anti-CD3 and 5 mg ml À1 anti-CD28. After 3 days, cells were harvested and CFSE signal in the gated CD4 + T cells was measured by flow cytometry (LSRII Flow Cytometer, BD Biosciences). Two or more independent experiments were performed.
Arginase and ROS assays
Arginase inhibitor N u -Hydroxy-nor-L-arginine was obtained from Sigma (#399275), and used at 100 mM. Recombinant human arginase 1 protein was obtained from Biolegend (#552502), and used at 1 mg/ml. To measure Arg1 activity, the Arginase Activity Assay Kit from Sigma (# MAK112) was used following manufacturer's instructions.
For ROS assay of MDSCs, the oxidation-sensitive dye Carboxy-H2DFFDA was obtained from Sigma (#C13293). Briefly, FACSsorted MDSC cells were incubated at 37 C in RPMI medium in the presence of 2.5 mM DCFDA for 30 min. For induced activation, cells were simultaneously cultured, along with DCFDA, with 30ng/ml PMA. Analysis was then conducted by flow cytometry as described above. Data are representative of two independent experiments.
T cell depletion and IL-1R acute inhibition T cell depletion was performed by intraperitoneal injection of anti-CD4 and anti-CD8 antibodies (400ug each for a single dose per mouse) every 7 days from day 7 post tumor cell injection. Antibodies were from BioXCell (clones GK1.5 and 53-6.72). Recombinant IL-1 receptor antagonist (IL-1Ra, anakinra) was from Biolegend (Cat#553908). IL1Ra was administered by i.v. injection at a dose of 2.5 mg/kg. Injections were performed daily for three consecutive days from day 9 after tumor cell injections. For experiments involving later time points, two additional injections were performed on day 13 and 14 after tumor cell injection. For each experiment, seven to nine mice were used for each group.
QUANTIFICATION AND STATISTICAL ANALYSIS
Student's t test (2-tailed) was applied to all analysis comparing between two groups of samples. For the T-cell depletion experiment, permutation-based tests were performed to evaluate statistical significance, using custom MATLAB codes. Specifically, we evaluated the probability to reject the null hypothesis that T cell depletion does not alter reduced tumor size phenotype in Mye-Tet2 null mice in comparison with mock treatment. This was performed by taking all possible ratios of tumor sizes between Tet2 null and WT groups (7 tumors per group, and thus 49 total possible ratios) under a specific treatment condition. The 49 ratios in T cell-depletion conditions were then compared to the 49 ratios in the mock group to derive a t test score. Permutations were then performed for 10,000 times by randomizing the labels of WT and Tet2 null assignment, and for each permutation, a t test score was derived by comparing the two sets of 49 ratios. Two-tailed p value was calculated as the probability of observing an equal or more extreme t test score in the permutation cases than the score of the original data. Similar tests were performed to reject the null hypothesis that T cell-depletion (in comparison to mock) has the same impact on Tet2 null groups as WT groups.
DATA AND SOFTWARE AVAILABILITY
Data have been deposited in Gene Expression Omnibus. The accession number for the sequencing data reported in this paper is GSE98964.
